PTC Therapeutics, Inc. – FDA CRL

PTC Therapeutics, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 220049) concerning vatiquinone oral capsules for Friedreich’s Ataxia (FA). The FDA determined that the application cannot be approved in its current state due to a lack of substantial evidence of effectiveness, a key regulatory requirement. The core issue lies with the single pivotal study, MOVE-FA, which failed to demonstrate a statistically significant benefit for its main efficacy goals, specifically on the modified Friedreich’s Ataxia Rating Scale (mFARS) and other key secondary measures. While PTC Therapeutics presented nominally significant results from exploratory analyses, such as the Upright Stability Subscale (USS), the FDA found these findings lacked sufficient statistical robustness, raised questions about their clinical significance, and were complicated by issues like baseline differences between patient groups and missing data. Additionally, data from the Modified Fatigue Impact Scale (MFIS) was deemed unsuitable for supporting efficacy due to interpretability concerns. The FDA also reviewed submitted real-world evidence and biomarker data intended as confirmatory support but found them insufficient. The agency stated it could not approve the application and advised PTC Therapeutics to address these data deficiencies to establish the required substantial evidence of effectiveness. The FDA indicated it would consider confirmatory evidence if a future submission includes a positive, adequate, and well-controlled study, alongside biomarker data adhering to FDA standards.